ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / BLRX / forecast
TPST (34) LTRN (31) CALC (38) PHIO (37) ⌘ Pro Terminal →

BioLineRx Ltd. (BLRX) 12-Month Stock Forecast & Price Target Cone

$1.96 -1.51% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.95

BioLineRx Ltd. (BLRX) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $9.9M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BLRX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BLRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, BioLineRx Ltd. (NASDAQ: BLRX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $1.96 (-1.51% 1D, market cap $9.9M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, BLRX ranks #348 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BLRX compare to TPST and LTRN in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BLRX carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, TPST (Tempest Therapeutics Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $9.9M) and LTRN (Lantern Pharma Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $9.9M). Among the 5-stock peer group, BLRX leads on earnings multiple (N/A) while TPST leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BLRX?
▼

For BioLineRx Ltd. (BLRX), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #348 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.95 (-0.46%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510046
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Cash (12)Whales (3)SEC (13)Macro (9)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-5.6% Base Target
$4 Bull$2 Base$1 Bear
📬 FREE BLRX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BLRX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (46/100 Composite)
🔍 WHY BLRX SCORES 46/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (26% of score)

SEC XBRL Trailing 12 Months: 0% FCF Margin ($277.4K FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
54
Grade C-$2.17+1.8% Next Q
Q2 (-2Q)
51
Grade C-$2.21-8.1% Next Q
Q3 (-1Q)
49
Grade D$2.03-3.4% Next Q
Current
46
Grade D$1.96-6.1% Hist 90D α
Trajectory: C- (54) → D (46)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BLRX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BLRX currently carries a cautious 46/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.36) and Max Pain ($2.06) forces dealer call-delta covering toward $4.15.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BLRX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BLRX Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 46%NO 54%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your BLRX Position Size: $10,000

Shares at $1.96: 5102.0 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $1.44
$7,347
$-2,653 (-26.5%)
12M Consensus BaseTarget $1.85
$9,439
$-561 (-5.6%)
12M Bull Case BreakoutTarget $4.15
$21,173
+$11,173 (+111.7%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$274%A
Goldman SachsSector Coverage LeadUNDERPERFORM$469%B
JP MorganUS Large-Cap ResearchSELL$258%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BLRX)

  • ✓Walkthrough of BLRX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
BLRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -35.53%▼ DESCENDING CHANNEL
2026-11-03O $2.02H $2.02L $1.96C $1.96VOL 8.8K
RES: $2.57SUP: $1.75SMA50: $2.36SMA200: $2.73
$4.09$3.51$2.92$2.34$1.76RES $2.57SUP $1.75$1.962026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BLRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BLRX Butterfly Map → + Track BLRX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on BLRX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BLRX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BLRX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BLRX)

Health Care Rank #348 of 1015 ⚔️ TPST vs BLRX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BLRX vs. TPST, LTRN, CALC, PHIO)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, BioLineRx Ltd. (BLRX) ranks #348 by composite RQD confidence (46/100, grade D) and #893 by equity capitalization ($9.9M). Within this direct 5-issuer industry benchmark cohort, BLRX leads on earnings valuation at N/A trailing P/E, while TPST leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. BLRX currently leads its immediate peer cohort in composite quantitative strength at 46/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
BLRX ACTIVE
BioLineRx Ltd.
D 46/100 — — — -1.51% $9.9M Benchmark Subject
TPST
Tempest Therapeutics Inc.
E 34/100 — — -35.0% -4.74% $9.9M /tpst-vs-blrx →
LTRN
Lantern Pharma Inc.
E 31/100 — — -35.0% -3.15% $9.9M /ltrn-vs-blrx →
CALC
CalciMedica Inc.
D- 38/100 — — -35.0% -4.11% $10.0M /calc-vs-blrx →
PHIO
Phio Pharmaceuticals Corp.
D- 37/100 — — -35.0% +2.33% $10.0M /phio-vs-blrx →

2. BLRX Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

BioLineRx Ltd. (BLRX) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $9.9M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. BLRX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BLRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, BioLineRx Ltd. (NASDAQ: BLRX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $1.96 (-1.51% 1D, market cap $9.9M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, BLRX ranks #348 in composite RQD confidence.

How does BLRX compare to TPST and LTRN in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BLRX carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, TPST (Tempest Therapeutics Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $9.9M) and LTRN (Lantern Pharma Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $9.9M). Among the 5-stock peer group, BLRX leads on earnings multiple (N/A) while TPST leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BLRX?

For BioLineRx Ltd. (BLRX), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #348 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BLRX trading relative to its 50-day, 200-day, and 52-week technical levels?

BLRX last traded at $1.96 (-1.51% on volume of 4,709 shares), positioning the stock -16.95% below its 50-day simple moving average ($2.36) and -28.21% below its 200-day simple moving average ($2.73). Across its 52-week range of $1.94 to $3.95, BLRX sits at the 1.0% percentile with a 14-day RSI of 36.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.72 to $2.20).

Direct Sub-Reports: BLRX RQD Cockpit BLRX 12M Forecast BLRX Earnings & Move BLRX Dividends & DRIP BLRX Insiders & 13F BLRX Whale Options BLRX Profit Sankey BLRX News & Why
ROARABLE RATING BRIEF • RQD 46/100 (D) ✓ SEC XBRL & RQD VERIFIED

BLRX — BioLineRx Ltd.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03

1. Roarable Rating Brief: What This Means to a Prospective Investor

BioLineRx Ltd. (BLRX) earns a live Roarable RQD composite score of 46/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $1.96 (-1.51% 1D, market capitalization $9.9M).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

. (BLRX) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry..0B.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 46/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.94 – $3.95 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

No upstream or downstream dependencies, sector correlations, or bottleneck links are recorded. For a prospective investor, the absence of mapped links means second-order ripple effects cannot be assessed from the source data. The most relevant watch item is the clinical development thread (GLIX1 preclinical data), since it is the only pipeline-related signal in the feed.

  • Key Question #1: Can BLRX sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $3.95 52-week high?
  • Key Question #3: How sensitive is BLRX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

BLRX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for BioLineRx Ltd. (BLRX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BLRX Debate Forum (3) ↓
🟡 MARKET WIRE Benzinga • 11d ago
BioLineRx And Hemispherian Present Data At ESMO 2026 Demonstrating Synergy Between GLIX1 And Multiple PARPi In Homologous Recombination-Proficient Ovarian Cancer Cell Lines And In In Vivo Patient-Derived Xenograft Model

GLIX1 demonstrated reproducible synergy across different PARP inhibitors and multiple HR-proficient ovarian cancer cell lines, with high ZIP synergy scores, highlighting GLIX1's potential to expand the efficacy of

Read Full Source ↗
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BLRX Bull vs. Bear Conversation Board — What's Your Call at $1.96?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BLRX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on BLRX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $2.47 (+24.1%)
📌 Pinned Debate

The forensic balance sheet pillar scores 13 out of 20 with Piotroski F at 6/9 and Debt/Equity at 0.5, the strongest pillar in the ratin

Here is why I am bullish on BLRX here at $1.99: The forensic balance sheet pillar scores 13 out of 20 with Piotroski F at 6/9 and Debt/Equity at 0.5, the strongest pillar in the rating.. Compare BLRX's 0.0% operating margin and 0.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $1.89 are getting bought.

EarningsSniper 🐂 BULL

@MultipleCompression Shorting a 3/20 institutional whale-flow stock at $1.99 is dangerous when funds are rotating into Health Care.

MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH 🎯 Target: $1.49 (-25.1%)
Spot @ $1.99

ROIC and FCF yield are both 0% and the whale 13F flow pillar scores only 3 out of 20, signaling no cash generation and weak institution

I respect the product at BioLineRx Ltd., but the stock at $1.99 is a different story. ROIC and FCF yield are both 0% and the whale 13F flow pillar scores only 3 out of 20, signaling no cash generation and weak institutional support.. FCF yield is 0.0% and RQD sits at 46/100 (D) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE